Wegovy cost without insurance (2026 guide)

Wegovy’s list price is $1,349 per month. That’s the number you’ll see at the pharmacy counter if you don’t have insurance coverage for it. The good news: almost nobody actually pays that amount. Between Novo Nordisk’s direct pricing programs, pharmacy discount cards, and compounded semaglutide alternatives, most people can access the same active ingredient for a fraction of the retail cost.

This guide breaks down every option available in 2026, with real numbers.

Quick cost comparison

Option	Monthly cost	What you get	Requires Rx?
Wegovy retail (cash pay)	~$1,349	Brand-name semaglutide 2.4mg injection	Yes
Wegovy via NovoCare (self-pay)	$149–$299	Brand-name, dose-dependent pricing	Yes
Wegovy savings card (insured)	As low as $25	Brand copay assistance, max $100/mo savings	Yes
GoodRx coupon	~$843–$1,100	Pharmacy discount on brand Wegovy	Yes
Compounded semaglutide	$179–$299	Same active ingredient, 503A/503B pharmacy	Yes

What Wegovy actually costs at the pharmacy

The wholesale acquisition cost (WAC) for Wegovy is $1,349.02 per month for a 28-day supply of any dose [1]. That’s the starting point. But retail pharmacies mark this up further. GoodRx reports average retail prices around $1,638 for the most common version [2].

The price stays the same whether you’re on the 0.25mg starter dose or the full 2.4mg maintenance dose. Each box contains four pre-filled pens for weekly injection.

For context, that’s $16,188 per year at list price. Over 68 weeks (the duration of the main clinical trial), you’d spend roughly $22,000 before even reaching the results shown in the STEP 1 study [3].

Novo Nordisk savings programs

Novo Nordisk runs two programs through NovoCare that can dramatically cut costs.

Wegovy savings card (for insured patients)

If you have commercial insurance that covers Wegovy, the savings card drops your copay to as low as $25 per month, with a maximum savings of $100 per 1-month fill [4]. The card is free to activate through NovoCare.

A few things to know: this doesn’t work with Medicare, Medicaid, or other government insurance. You need a valid prescription, and your plan must already include Wegovy on its formulary. The card handles the gap between what your insurance pays and the retail price.

NovoCare self-pay pricing (no insurance needed)

This is the better option for uninsured patients. Novo Nordisk offers direct self-pay pricing through the NovoCare Pharmacy:

• 0.25mg and 0.5mg (titration doses): $199/month for new patients (promotional pricing through June 30, 2026) [4]
• 1.5mg and 4mg doses: $149/month [5]
• 2.4mg maintenance dose: $199–$299/month depending on current promotions

These prices are only available through the NovoCare Pharmacy, not your local CVS or Walgreens. You order directly from Novo Nordisk’s fulfillment partner.

The catch: promotional pricing changes frequently. The $199 introductory offer for titration doses was originally set to expire March 31, 2026, but has been extended through June 2026 for new patients [4]. Check the NovoCare website for current terms.

Pharmacy discount cards and coupons

If the NovoCare Pharmacy doesn’t work for you (some patients prefer a local pharmacy or need same-day pickup), pharmacy discount cards can help.

GoodRx currently shows prices as low as $149 at select pharmacies, though availability varies by location [2]. The more typical GoodRx-discounted price runs $843–$1,100 depending on your pharmacy and dose.

SingleCare reports similar savings, with prices around $843 at participating locations [6].

These coupons can’t be combined with insurance or the Novo Nordisk savings card. They work best for patients paying entirely out of pocket at a retail pharmacy.

Why Wegovy costs so much

Semaglutide isn’t expensive to manufacture. The high price reflects Novo Nordisk’s monopoly on the brand-name formulation, the cost of running clinical trials (the STEP program enrolled over 15,000 participants across multiple studies), and the standard pharmaceutical pricing model in the U.S. [3].

Other countries pay far less. Canada and the UK negotiate prices that are roughly 40–60% lower than U.S. retail [7].

The February 2026 FDA actions on compounding have created new competitive dynamics. While the FDA has attempted to restrict compounded versions of some GLP-1 medications, compounded semaglutide remains available through properly licensed 503A and 503B pharmacies during ongoing legal proceedings [8].

Compounded semaglutide: the affordable alternative

Compounded semaglutide uses the same active ingredient as Wegovy but is prepared by licensed compounding pharmacies rather than Novo Nordisk. The result is the same molecule at a significantly lower price.

How it works

A licensed prescriber writes a prescription for compounded semaglutide. A 503A or 503B compounding pharmacy prepares the medication in the prescribed dose. It’s shipped directly to you, typically as a multi-dose vial for subcutaneous injection.

The active ingredient is identical: semaglutide. What differs is the manufacturing process, the delivery device (vials and syringes instead of pre-filled pens), and the price.

What it costs

Most telehealth providers offering compounded semaglutide charge between $179 and $299 per month, including the provider consultation and medication [9]. That’s 78–87% less than Wegovy’s list price.

At PURE Peptide Clinic, compounded semaglutide programs include the medical consultation, ongoing provider access, and medication from a licensed 503B pharmacy.

Is it as effective?

The active molecule is the same. A 2024 study in Pharmaceutical Research examined the quality of compounded semaglutide products and found that properly manufactured compounded formulations maintained comparable pharmaceutical properties to the brand product [10]. What matters is the pharmacy’s quality controls and the prescriber’s dosing protocol.

The STEP 1 trial showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks compared to 2.4% with placebo [3]. Whether that semaglutide comes from Novo Nordisk or a licensed 503B pharmacy, the molecule does the same thing once it’s in your body.

Safety considerations

Compounded medications are not FDA-approved as finished products, but the pharmacies that make them are regulated by state boards of pharmacy and (for 503B facilities) inspected by the FDA [8]. The key is choosing a provider that sources from a reputable 503B outsourcing facility.

Read more about safety in our guide on whether compounded semaglutide is safe and how 503A vs 503B pharmacies differ.

How to save the most on Wegovy (or its equivalent)

The best path depends on your insurance situation:

If you have commercial insurance that covers Wegovy: Use the Novo Nordisk savings card. Your cost drops to $25–$150/month.

If you have insurance that doesn’t cover Wegovy: Check the NovoCare self-pay program first ($149–$299/month for brand Wegovy). Compare that to compounded semaglutide pricing.

If you have no insurance at all: Compounded semaglutide through a telehealth provider is usually the most affordable option at $179–$299/month, including the consultation. The NovoCare self-pay program is competitive at certain dose levels.

If you’re on Medicare or Medicaid: Government insurance programs don’t accept manufacturer savings cards. If your plan doesn’t cover Wegovy, compounded semaglutide may be your best bet. Medicare Part D now has a $2,000 out-of-pocket cap as of 2025 that may help if your plan does cover it.

How semaglutide works (quick overview)

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut naturally produces after eating, which signals your brain to reduce appetite and slow gastric emptying [3].

The STEP 1 trial (1,961 participants, 68 weeks) showed an average weight loss of 14.9% of body weight with semaglutide 2.4mg plus lifestyle intervention [3]. The most common side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). Most of these are mild to moderate and decrease over time as the dose titrates up.

For a deeper look at how semaglutide stacks up against tirzepatide, see our semaglutide vs tirzepatide comparison. And for a broader overview of peptides for weight loss, we cover every option available.

FAQ

Is there a generic version of Wegovy?▼

No. Novo Nordisk holds patents on semaglutide that won’t expire for several more years. Compounded semaglutide is not a generic; it’s a compounded preparation of the same active ingredient made by a licensed pharmacy.

Can I use the Wegovy savings card without insurance?▼

The savings card is designed for patients with commercial insurance. However, Novo Nordisk’s NovoCare self-pay program is specifically designed for uninsured patients, with pricing starting at $149/month for certain doses.

How much does Wegovy cost per year without any discounts?▼

At the list price of $1,349/month, a full year of Wegovy costs approximately $16,188. With NovoCare self-pay pricing, annual costs range from $1,788 to $3,588 depending on dose.

Is compounded semaglutide legal?▼

Yes. Compounding pharmacies are regulated under federal law (FDCA sections 503A and 503B) and state pharmacy boards. The legality of compounding specific drugs depends on FDA shortage designations and ongoing regulatory actions. As of early 2026, compounded semaglutide remains available through licensed pharmacies. See our legal guide for more detail.

Does Wegovy come in a pill form?▼

Yes. Novo Nordisk received FDA approval for an oral semaglutide formulation for weight management. The oral version has the same list price as the injection ($1,349/month) but may have different pricing through NovoCare.

How long do I need to take Wegovy?▼

The clinical trials ran for 68 weeks. Studies show that most weight is regained after stopping the medication [11]. Most prescribers recommend ongoing treatment, which makes long-term cost a real consideration in choosing between brand Wegovy and more affordable alternatives.

Can I switch from Wegovy to compounded semaglutide?▼

Yes, with your prescriber’s guidance. Since the active ingredient is the same, switching is straightforward. Your provider will match your current dose and adjust as needed.

Will insurance ever cover Wegovy for weight loss?▼

Coverage is expanding. More commercial plans added GLP-1 coverage in 2025–2026, and Medicare’s Inflation Reduction Act provisions have improved access for some beneficiaries. But coverage is still far from universal.

The bottom line

Nobody should pay $1,349/month for semaglutide in 2026. Between Novo Nordisk’s own self-pay programs ($149–$299/month), pharmacy coupons, and compounded semaglutide ($179–$299/month), there are real options for every budget and insurance situation.

If you’re interested in compounded semaglutide, check whether you qualify for a prescription through our telehealth program.

References

1. Novo Nordisk. Wegovy® (semaglutide) injection 2.4 mg prescribing information and pricing. NovoCare. 2026.
2. GoodRx. Wegovy prices, coupons and savings tips. https://www.goodrx.com/wegovy. Accessed April 2026.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
4. Novo Nordisk. Wegovy savings offer terms and conditions. NovoCare. Updated 2026. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
5. Novo Nordisk. Wegovy savings card, cost & coverage support. Wegovy.com. 2026. https://www.wegovy.com/coverage-and-savings/save-on-wegovy.html
6. SingleCare. Ozempic and Wegovy coupons and prices. https://www.singlecare.com/prescription/wegovy. Accessed April 2026.
7. Patented Medicine Prices Review Board (PMPRB). Annual Report 2024. Government of Canada.
8. FDA. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration. Updated 2026.
9. Telehealth provider pricing surveys. Pure Peptide Clinic market research. 2026.
10. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharm Res. 2024. https://pubmed.ncbi.nlm.nih.gov/39379664/
11. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap. Cureus. 2026. https://pubmed.ncbi.nlm.nih.gov/41909366/